ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 218.60 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-08-12
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-06-30 was 161.71K shares, a 154.16% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 56.89K shares, a 55.47% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-12-31 was 54.43K shares, a 1530.04% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 90.87K shares, a 323.66% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 245.51K shares, a 87.45% increase from fiscal 2024.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 130.97K shares, a 0.91% decline from fiscal 2023.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 132.18K shares, a 42.85% increase from fiscal 2022.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 92.53K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 161.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 218.60K shares 10-Q · filed 2026-08-12 | 273.02K shares derived: sum of 3 quarters · filed 2026-08-12 | 363.89K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 56.89K shares 10-Q · filed 2026-05-07 | 111.31K shares derived: sum of 2 quarters · filed 2026-05-07 | 202.19K shares derived: sum of 3 quarters · filed 2026-05-07 | 265.81K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 54.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 145.30K shares derived: sum of 2 quarters · filed 2026-03-30 | 208.92K shares derived: sum of 3 quarters · filed 2026-03-30 | 245.51K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 90.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 154.49K shares derived: sum of 2 quarters · filed 2025-11-10 | 191.09K shares 10-Q · filed 2025-11-10 | 194.42K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 63.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 100.22K shares 10-Q · filed 2025-08-14 | 103.55K shares derived: sum of 3 quarters · filed 2025-08-14 | 125.00K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 36.59K shares 10-Q · filed 2025-05-12 | 39.93K shares derived: sum of 2 quarters · filed 2025-05-12 | 61.38K shares derived: sum of 3 quarters · filed 2025-05-12 | 109.94K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 3.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 24.79K shares derived: sum of 2 quarters · filed 2025-03-03 | 73.35K shares derived: sum of 3 quarters · filed 2025-03-03 | 130.97K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 21.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 70.01K shares derived: sum of 2 quarters · filed 2024-11-14 | 127.64K shares 10-Q · filed 2024-11-14 | 154.81K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 48.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 106.19K shares 10-Q · filed 2024-08-12 | 133.36K shares derived: sum of 3 quarters · filed 2024-08-12 | 171.60K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 57.62K shares 10-Q · filed 2024-05-13 | 84.80K shares derived: sum of 2 quarters · filed 2024-05-13 | 123.04K shares derived: sum of 3 quarters · filed 2024-05-13 | 142.00K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 27.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 65.41K shares derived: sum of 2 quarters · filed 2024-03-26 | 84.38K shares derived: sum of 3 quarters · filed 2024-03-26 | 132.18K shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 38.24K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 57.20K shares derived: sum of 2 quarters · filed 2023-11-13 | 105.00K shares 10-Q · filed 2023-11-13 | 138.56K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 18.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 66.76K shares 10-Q · filed 2023-08-07 | 100.32K shares derived: sum of 3 quarters · filed 2023-08-07 | 100.32K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 47.80K shares 10-Q · filed 2023-05-08 | 81.35K shares derived: sum of 2 quarters · filed 2023-05-08 | 81.35K shares derived: sum of 3 quarters · filed 2023-05-08 | 101.05K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 33.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 33.55K shares derived: sum of 2 quarters · filed 2023-03-06 | 53.25K shares derived: sum of 3 quarters · filed 2023-03-06 | 92.53K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 19.70K shares derived: sum of 2 quarters · filed 2022-11-03 | 58.98K shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 19.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 58.98K shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 39.28K shares 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |